TIDMSHP
Result of the 2017 Annual General Meeting
April 25, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that, at its Annual General Meeting held at The Merrion Hotel, Upper Merrion
Street, Dublin 2, Ireland at 2.45pm today, all resolutions contained in the
Notice of Meeting were decided by poll vote. The results of the poll are as
follows:
Resolutions For % Against % Votes Withheld
(including cast as a
discretionary % of
votes) relevant
shares in
issue
Ordinary Resolutions
1. To receive the 654,818,375 98.84% 7,707,875 1.16% 73.04% 4,881,183
Company's Annual Report
and Accounts for the year
ended December 31, 2016.
2. To approve the 615,163,095 93.22% 44,723,057 6.78% 72.75% 7,521,281
Directors' Remuneration
Report.
3. To re-elect Dominic 649,117,820 98.05% 12,928,333 1.95% 72.99% 5,361,280
Blakemore as a Director.
4. To re-elect Olivier 627,642,447 94.87% 33,920,776 5.13% 72.94% 5,844,210
Bohuon as a Director.
5. To re-elect William 665,784,255 99.86% 960,666 0.14% 73.51% 662,512
Burns as a Director.
6. To elect Ian Clark as 651,027,149 97.63% 15,797,431 2.37% 73.52% 582,853
a Director.
7. To elect Gail Fosler 661,335,866 99.18% 5,499,058 0.82% 73.52% 572,509
as a Director.
8. To re-elect Steven 635,977,566 95.40% 30,649,403 4.60% 73.50% 780,464
Gillis as a Director.
9. To re-elect David 666,231,111 99.91% 593,588 0.09% 73.52% 582,734
Ginsburg as a Director.
10. To re-elect Susan 659,834,334 99.01% 6,565,404 0.99% 73.47% 1,007,695
Kilsby as a Director.
11. To re-elect Sara 660,030,658 98.98% 6,802,836 1.02% 73.52% 573,939
Mathew as a Director.
12. To re-elect Anne 657,515,406 99.31% 4,576,118 0.69% 73.00% 5,315,909
Minto as a Director.
13. To re-elect Flemming 666,498,607 99.95% 322,419 0.05% 73.52% 586,407
Ornskov as a Director.
14. To re-elect Jeffrey 663,597,002 99.51% 3,236,158 0.49% 73.52% 574,273
Poulton as a Director.
15. To elect Albert 660,769,699 99.09% 6,047,544 0.91% 73.52% 590,190
Stroucken as a Director.
16. To re-appoint 596,710,936 89.64% 68,985,657 10.36% 73.39% 1,710,840
Deloitte LLP as the
Company's Auditor.
17. To authorize the 613,970,704 92.24% 51,651,020 7.76% 73.39% 1,785,709
Audit, Compliance & Risk
Committee to determine
the remuneration of the
Auditor.
18. To authorize the 622,880,755 93.40% 43,989,439 6.60% 73.52% 537,239
allotment of shares.
Special Resolutions
19. To authorize the 647,605,695 97.72% 15,078,442 2.28% 73.06% 4,723,296
general disapplication of
pre-emption rights.
20. To authorize the 632,770,742 95.48% 29,932,382 4.52% 73.06% 4,704,309
specific disapplication
of pre-emption rights.
21. To authorize 658,828,861 98.87% 7,499,007 1.13% 73.46% 1,079,565
purchases of own shares.
22. To adopt new Articles 660,636,265 99.08% 6,130,317 0.92% 73.51% 640,851
of Association.
23. To approve the notice 619,638,682 93.34% 44,232,588 6.66% 73.19% 3,536,163
period for general
meetings.
As at the record date, April 23, 2017, the Company had 907,025,186 Ordinary
Shares of 5 pence each in issue (excluding shares held in treasury).
Shareholders are entitled to one vote per share. A vote "withheld" is not a
vote in law and is not counted in the calculation of the proportion of votes
validly cast.
In accordance with Listing Rule 9.6.2R, copies of the relevant resolutions
passed at the meeting have been submitted to the National Storage Mechanism and
will be available for viewing shortly at: www.morningstar.co.uk/uk/nsm.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
Investor Relations
Ian Karp ikarp@shire.com +1 781 482 9018
Robert Coates rcoates@shire.com +44 1256 894874
Media
Lisa Adler lisa.adler@shire.com +1 617 588 8607
Debbi Ford debbi.ford@shire.com +1 617 949 9083
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people
with rare diseases. We strive to develop best-in-class products, many of which
are available in more than 100 countries, across core therapeutic areas
including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage
Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary
Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
www.shire.com
END
(END) Dow Jones Newswires
April 25, 2017 11:15 ET (15:15 GMT)
Shire (LSE:SHP)
Historical Stock Chart
From Apr 2024 to May 2024
Shire (LSE:SHP)
Historical Stock Chart
From May 2023 to May 2024